Essential Oils Managed as Medication Note (Institutional Policy)

Date/Time: [Date and time of documentation]

Location/Unit: [Location or unit]

Author/Credentials: [Author name and credentials]

Cosigner: [Cosigner name and credentials] (Include only if required by institutional policy)

Product & Authorization

• Product: [Display name] — [Common name] ([Latin binomial])
• Form/Vehicle: [neat oil / diluted roll-on / diffuser blend / other]
• Source: [patient-supplied / facility-supplied / integrative medicine department]
• Route: [inhalation / topical / diffusion / other]
• Dose and Frequency: [Dose with units and schedule] (Include drops, dilution percentage, or diffusion duration as applicable to route.)
• Start Date: [Start date] — Stop Date/Criteria: [Stop date or explicit stop criteria]
• Ordering/Authorizing Clinician: [Name, credentials] — [Order date] — Status: [new / continue / modify / discontinue]
• Pharmacy Verification: [verified / pending / not required] (Include only if required by policy.)
• Verification Status: [product identity/concentration/route verified / held pending evaluation] (If any element cannot be verified, document reason and do not proceed until resolved.)
• Unauthorized Use Variance: [N/A / yes] (If yes, describe event, immediate mitigation, and notification per policy.)

Intended Use & Safety Screen

• Clinical Intent: [Target symptom or condition]
• Therapeutic Rationale Source: [patient-stated / clinician-stated / product labeling]
• Regulatory Framing: [Policy-compliant statement, e.g., complementary therapy, not a substitute for standard care]
• Safety Screening Completed: [yes / no] — [Date]
  • Allergy/Fragrance Sensitivity: [positive / negative / unknown] — [Details if positive]
  • Respiratory Risk: [positive / negative / N/A] — [Details] (Required for inhaled or diffused routes.)
  • Interaction Assessment: [concern identified / none identified] — [Sources consulted] (Do not claim absence of interactions without documenting basis.)
  • Population Considerations: [pregnancy / pediatric / geriatric / N/A] — [Details if applicable]
• Safety Decision: [proceed / hold / contraindicated] — [Mitigation actions if applicable]

Administration & Monitoring

• Route-Specific Instructions:
  • Inhalation: [Device type] — [Drops] — [Frequency] — [Session duration] (Include if applicable.)
  • Topical: [Dilution %] in [Carrier] — [Application site] — [Amount] — [Frequency] (Include if applicable.)
  • Diffusion: [Location] — [Drops/volume] — [Duration] — [Environmental restrictions] (Include if applicable.)
• Stop Criteria: [Adverse effects requiring discontinuation, e.g., rash, respiratory symptoms, intolerance]
• Monitoring: [Parameters to observe] — Reassessment: [Timeframe]
• Adverse Event Escalation: [Who to notify and immediate steps if reaction occurs]

Handling & Disposition

• Custody/Storage: [patient possession / secured storage] — Labeling: [compliant / corrections made]
• Administration Documentation: [MAR/flowsheet reference or order ID]
• Discharge Disposition: [returned to patient / discarded per policy / dispensed with labeling and education] — [Recipient name if returned]
• Medication Reconciliation: [continue / discontinue at discharge] — [Instructions to patient and receiving provider]
• Outstanding Clarifications: [Unknown or missing elements and plan to resolve, or N/A] (Hold administration if required information is unclear.)